Antibiotics, Antitubercular
"Antibiotics, Antitubercular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
| Descriptor ID |
D000904
|
| MeSH Number(s) |
D27.505.954.122.085.255.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antitubercular".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antitubercular".
This graph shows the total number of publications written about "Antibiotics, Antitubercular" by people in this website by year, and whether "Antibiotics, Antitubercular" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibiotics, Antitubercular" by people in Profiles.
-
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
-
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021 02 11; 76(3):582-586.
-
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2020 09 15; 202(6):866-877.
-
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrob Agents Chemother. 2019 04; 63(4).
-
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
-
In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2017 08 01; 72(8):2320-2325.
-
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017 Aug; 102(2):321-331.
-
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015 Feb 01; 191(3):333-43.
-
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun; 58(6):3035-42.
-
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012 Oct 01; 206(7):1030-40.